Psychedelics

It appeared Health Canada was increasing access to the substance, but recent events suggest otherwise

Stock will start trading at market open Thursday under the symbol NUMIF

Expenses were down 71% but the firm still reported a $5.4-million loss

Two separate trials will look at MDMA for alcohol use and PTSD, as well as psilocybin-assisted therapy for anorexia nervosa

If approved, it will mark the firm's first independent clinical trial with a proprietary extract

Following the trial's approval from Health Canada, psychedelic practitioners can now apply to be research subjects

The new rules will facilitate safer access to substances like psilocybin, but many in need won't qualify, experts say

Currently treatments are largely insufficient, so care providers encourage more research despite stigma

Psychedelics firm Numinus says amendments made to the country's Special Access Programme come into effect in January

The psychedelics firm has been aggressively expanding lab space while pushing ahead with clinical trials

The new facility will feature the firm's ketamine-assisted therapy program, as well as a range of health and lifestyle services

The methods will be available as part of third-party client services

Some are criticizing researcher Stamets for trying to capitalize on the phenomenon of 'stacking,' where psychedelics are paired with health supplements

Cannabis and 'classical' psychedelics could act on similar receptors

Conservative MP and drug policy reform chair Crispin Blunt suggests reclassifying the substance to a less severe category of the country's drug law

It’s the first federal grant to be awarded for psychedelic treatment research in 50 years

When asked why patient requests for legal psilocybin are being denied or delayed, the agency said studies are the best route for access

TheraPsil's CEO expects change for psilocybin to come in a matter of months because of the work done for cannabis

Advocacy group TheraPsil is teaming up with lawyers to pressure the government to grant access and develop regulations

Psilocybin has a restorative effect on neurons in frontal areas of the brain, according to researchers at Yale University

The Vancouver based firm is acquiring the Neurology Centre of Toronto in a cash and stock deal

The psychedelic movement is no longer about anecdotes, experts say

If Bill SB-519 passes, possession of psychedelics for personal would be decriminalized, but cultivation and sale is still outlawed

After drinking the psychedelic plant brew together, Jewish-Israeli and Arab-Palestinian participants reported moments of deep connection, unity and oneness

Toronto-based Field Trip launched two new polls that show more people are open to using psychedelics to treat rising pandemic-related mental health issues

Writer Suzannah Weiss details her experience of physical and mental healing, accompanied by comic illustrations

After two years of dispute, MAPS is celebrating the decision

Study aims to prove safety of psilocybe mushrooms so Canadian regulators can expand access to psychedelic therapy

The first head-to-head clinical trial pushes the psychedelic compound closer to becoming a licensed medicine

Vancouver activist Dana Larsen is pushing the drug-reform conversation past cannabis by opening the doors of his entheogenic coffee shop

Early evidence shows LSD promotes social behaviour in rodents, but pharmaceutical research is still a ways off

A recent review suggests natural settings and activities can complement all stages of psychedelic-assisted therapy

With solid efficacy and low cost, the popular club drug could help curb the personal toll and multi-billion dollar cost of North America's battle with depression

Proposed by Health Canada, the change would allow patients to access restricted substances like MDMA through the Special Access Program

With major research, legal reform, and more than 20 firms going public, it was major year for the re-emerging field

Following a surge of interest, ibogaine therapy in the country disappeared. But recent signs show regulators are warming to the promising plant

After a successful ballot measure, a broad set of onlookers focuses on Oregon to gauge the social and economic impacts of licensed psilocybin therapy

Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine

A first-of-its-kind clinical trial shows a dramatic drop in depression in over half of patients who received a synthetic version of the compound

In September, the Michigan city halted enforcement related to all entheogenic plants. Officials hope the move will inspire other moderate jurisdictions